title: Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.
abstract: Enteropathy associated T-cell lymphoma (EATL) is a rare type of peripheral T-cell lymphoma. At present, there are no standardized diagnostic or treatment protocols for EATL. We describe EATL in a population-based setting and evaluate a new treatment with aggressive chemotherapy and autologous stem cell transplantation (ASCT). From 1979 onward the Scotland and Newcastle Lymphoma Group prospectively collected data on all patients newly diagnosed with lymphoma in the Northern Region of England and Scotland. Between 1994 and 1998, records of all patients diagnosed with EATL were reviewed, and 54 patients had features of EATL. Overall incidence was 0.14/100 000 per year. Treatment was systemic chemotherapy (mostly anthracycline-based chemotherapy) with or without surgery in 35 patients and surgery alone in 19 patients. Median progression-free survival (PFS) was 3.4 months and overall survival (OS) was 7.1 months. The novel regimen IVE/MTX (ifosfamide, etoposide, epirubicin/methotrexate)-ASCT [corrected] was piloted from 1998 for patients eligible for intensive treatment, and 26 patients were included. Five-years PFS and OS were 52% and 60%, respectively, and were significantly improved compared with the historical group treated with anthracycline-based chemotherapy (P = .01 and P = .003, respectively). EATL is a rare lymphoma with an unfavorable prognosis when treated with conventional therapies. The IVE/MTX-ASCT regimen is feasible with acceptable toxicity and significantly improved outcome.
authors.affiliation: Haematological Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom. michal.sieniawski@ncl.ac.uk
authors.forename: Michal
authors.initials: M
authors.lastname: Sieniawski
authors.forename: Nithia
authors.initials: N
authors.lastname: Angamuthu
authors.forename: Kathryn
authors.initials: K
authors.lastname: Boyd
authors.forename: Richard
authors.initials: R
authors.lastname: Chasty
authors.forename: John
authors.initials: J
authors.lastname: Davies
authors.forename: Peter
authors.initials: P
authors.lastname: Forsyth
authors.forename: Fergus
authors.initials: F
authors.lastname: Jack
authors.forename: Simon
authors.initials: S
authors.lastname: Lyons
authors.forename: Philip
authors.initials: P
authors.lastname: Mounter
authors.forename: Paul
authors.initials: P
authors.lastname: Revell
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Proctor
authors.forename: Anne L
authors.initials: AL
authors.lastname: Lennard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002446:Celiac Disease / Q000150:complications / Q000628:therapy*; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D016411:Lymphoma, T-Cell, Peripheral / Q000150:complications / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011446:Prospective Studies; D012606:Scotland / Q000453:epidemiology; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D007069:Ifosfamide; D008727:Methotrexate